64Cu-DOTA-daratumumab

N/A

Report date: 2025/09/24 17:41:44

Base Information

Drug Name64Cu-DOTA-daratumumab
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive diagnostic agent +[5] 
Mechanisms of ActionLymphocyte differentiation antigen CD38 inhibitors
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCity Of Hope National Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesCity Of Hope National Medical Center
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A